

Ref. No: 2338
Date: 03/02/26
Subject: Biologics Medicines in Gastroenterology

REQUEST & RESPONSE

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira <5
- Adalimumab Biosimilar 153
- Etrasimod 0
- Filgotinib 12
- Golimumab <5
- Infliximab – Remicade <5
- Infliximab Biosimilar 279
- Mirikizumab 23
- Ozanimod <5
- Risankizumab 20
- Tofacitinib 15
- Upadacitinib 33
- Ustekinumab – Stelara 17
- Ustekinumab Biosimilar 140
- Vedolizumab 125
- Guselkumab 0

Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab – Humira 0
- Adalimumab Biosimilar 18
- Etrasimod 0
- Filgotinib 0
- Golimumab <5
- Infliximab – Remicade 0

- Infliximab Biosimilar 9
- Mirikizumab <5
- Ozanimod 0
- Risankizumab <5
- Tofacitinib <5
- Upadacitinib <5
- Ustekinumab – Stelara 0
- Ustekinumab Biosimilar <5
- Vedolizumab 33
- Guselkumab 0

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification